The company completed a $100 million round C financing

A clinical CRO with a solid layout at two of the world's largest pharmaceutical markets and drug research and development bases in China and the United States today announced the successful completion of a $100 million round of C-round financing.
this round of financing is led by Fidelity Management and Research Company, LLC, and is also involved in this round of investments by Sequoia Capital China Fund, Kaiser Medical and Esfonda Capital.
's new investors have further strengthened a strong investor portfolio dominated by Qiming Ventures, Lilly Asia Fund and Vico Capital, the three former shareholders who have led the financing of the Angel Wheel, A Wheel and B Wheel since the company was established in 2016, respectively, and continue to increase their investment in the Company.
's unique positioning has attracted investors' attention -- providing local services to innovative Chinese biotech companies while helping them enter the U.S. market.
fact, overseas biopharmaceutical companies want to use trusted partners such as the network to guide them in unfamiliar clinical development and regulatory environments in China.
addition to international investment institutions, China's open capital market investment institutions also expressed their delight at being able to participate in the growth of the network.
。